GPR35; HTR1E; FFAR1; HTR1F; FFAR4; HTR7; HTR4; HTR1B; DRD4; ADORA3; HTR5A; ADRA2C; ADRA2A; ADRA2B; HTR1D; HTR2B; HTR2A; HTR2C; HTR6; GPBAR1; DRD3; DRD2; HTR1A; | |
TSHR; NPSR1; CXCR1; NMUR2; | |
PLA2G1B; TDP1; APOBEC3G; GLA; FAAH; RECQL; CTDSP1; TERT; PIK3CG; PIK3R1; GLO1; HPGD; MPO; HSD17B1; AKR1B1; HSD17B10; ALOX15; HSD11B1; ALDH1A1; HSD17B2; ALOX12; AKR1B10; NOX4; USP2; BRCA1; TNKS; PARP1; TNKS2; PYGL; APEX1; POLB; | |
PTPN1; CDC25B; PTPN2; PTPRF; ACP1; | |
ACHE; GAA; | |
HDAC3; | |
HTR3A; | |
TOP2A; | |
AKT1; MET; CAMK2B; NEK6; CSNK2A1; DAPK1; SYK; AXL; FLT3; SRC; IGF1R; PTK2; AURKB; INSR; CDK1; MAPK1; PIM1; NUAK1; ALK; GSK3B; MYLK; NEK2; KDR; PKN1; | |
CA5B; CA5A; CA3; CA14; CA7; CA1; CA9; CA4; CA6; CA2; CA12; | |
AR; NR3C2; PGR; NR3C1; | |
NR1I2; | |
PPARA; PPARG; PPARD; | |
ESRRA; | |
RORC; | |
NR1H4; | |
KDM4E; | |
MAOA; PTGS1; ALOX5; TYR; XDH; | |
MMP13; MMP3; MMP2; MMP9; MMP1; | |
CTSD; BACE1; | |
TLR2; | |
AHR; STAT6; HIF1A; NFKB1; TP53; | |
ABCC1; ABCB1; ABCG2; | |
SLC22A8; SLC22A6; SLC22A3; SLC22A1; SLCO1B3; SLCO1B1; | |
LMNA; FABP5; SERPINA6; FABP2; FABP4; MAPT; FABP3; THPO; SIGMAR1; RAB9A; NPC1; APP; | |
L3MBTL1; SMN1;SMN2; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
5HT3 receptor | HTR3A | Serotonin 3a (5-HT3a) receptor | P46098 | CHEMBL1899 |
Aspartic protease | CTSD | Cathepsin D | P07339 | CHEMBL2581 |
Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
ATP-binding cassette | ABCB1 | P-glycoprotein 1 | P08183 | CHEMBL4302 |
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
Enzyme_unclassified | PIK3CG | PI3-kinase p110-gamma subunit | P48736 | CHEMBL3267 |
Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
Enzyme_unclassified | BRCA1 | Breast cancer type 1 susceptibility protein | P38398 | CHEMBL5990 |
Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | APOBEC3G | DNA dC->dU-editing enzyme APOBEC-3G | Q9HC16 | CHEMBL1741217 |
Enzyme_unclassified | GLA | Alpha-galactosidase A | P06280 | CHEMBL2524 |
Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | CTDSP1 | Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 | Q9GZU7 | CHEMBL1795098 |
Histone deacetylase | HDAC3 | Histone deacetylase 3 | O15379 | CHEMBL1829 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
Isomerase | TOP2A | DNA topoisomerase II alpha | P11388 | CHEMBL1806 |
Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
Nuclear hormone receptor subfamily 1 group I | NR1I2 | Pregnane X receptor | O75469 | CHEMBL3401 |
Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
Nuclear hormone receptor subfamily 3 group C | NR3C2 | Mineralocorticoid receptor | P08235 | CHEMBL1994 |
Nuclear hormone receptor subfamily 3 group C | PGR | Progesterone receptor | P06401 | CHEMBL208 |
Nuclear hormone receptor subfamily 3 group C | NR3C1 | Glucocorticoid receptor | P04150 | CHEMBL2034 |
Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
Protein Kinase | MYLK | Myosin light chain kinase, smooth muscle | Q15746 | CHEMBL2428 |
Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
Protein Phosphatase | PTPRF | Receptor-type tyrosine-protein phosphatase F (LAR) | P10586 | CHEMBL3521 |
Protein Phosphatase | ACP1 | Low molecular weight phosphotyrosine protein phosphatase | P24666 | CHEMBL4903 |
SLC superfamily of solute carriers | SLC22A8 | Solute carrier family 22 member 8 | Q8TCC7 | CHEMBL1641348 |
SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
SLC superfamily of solute carriers | SLC22A3 | Solute carrier family 22 member 3 | O75751 | CHEMBL2073673 |
SLC superfamily of solute carriers | SLC22A1 | Solute carrier family 22 member 1 | O15245 | CHEMBL5685 |
SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
Small molecule receptor (family A GPCR) | HTR1E | Serotonin 1e (5-HT1e) receptor | P28566 | CHEMBL2182 |
Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
Small molecule receptor (family A GPCR) | HTR1F | Serotonin 1f (5-HT1f) receptor | P30939 | CHEMBL1805 |
Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
Small molecule receptor (family A GPCR) | HTR7 | Serotonin 7 (5-HT7) receptor | P34969 | CHEMBL3155 |
Small molecule receptor (family A GPCR) | HTR4 | Serotonin 4 (5-HT4) receptor | Q13639 | CHEMBL1875 |
Small molecule receptor (family A GPCR) | HTR1B | Serotonin 1b (5-HT1b) receptor | P28222 | CHEMBL1898 |
Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
Small molecule receptor (family A GPCR) | HTR5A | Serotonin 5a (5-HT5a) receptor | P47898 | CHEMBL3426 |
Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
Small molecule receptor (family A GPCR) | HTR1D | Serotonin 1d (5-HT1d) receptor | P28221 | CHEMBL1983 |
Small molecule receptor (family A GPCR) | HTR2B | Serotonin 2b (5-HT2b) receptor | P41595 | CHEMBL1833 |
Small molecule receptor (family A GPCR) | HTR2A | Serotonin 2a (5-HT2a) receptor | P28223 | CHEMBL224 |
Small molecule receptor (family A GPCR) | HTR2C | Serotonin 2c (5-HT2c) receptor | P28335 | CHEMBL225 |
Small molecule receptor (family A GPCR) | HTR6 | Serotonin 6 (5-HT6) receptor | P50406 | CHEMBL3371 |
Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
Small molecule receptor (family A GPCR) | DRD3 | Dopamine D3 receptor | P35462 | CHEMBL234 |
Small molecule receptor (family A GPCR) | DRD2 | Dopamine D2 receptor | P14416 | CHEMBL217 |
Small molecule receptor (family A GPCR) | HTR1A | Serotonin 1a (5-HT1a) receptor | P08908 | CHEMBL214 |
Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Unclassified | SERPINA6 | Corticosteroid binding globulin | P08185 | CHEMBL2421 |
Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Unclassified | SIGMAR1 | Sigma opioid receptor | Q99720 | CHEMBL287 |
Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | Unclassified; | GO:0099600; transmembrane receptor activity | 1.312E-12 | 3.008E-10 | ADORA3, ADRA2A, ADRA2B, ADRA2C, ALK, AXL, CXCR1, DRD2, DRD3, DRD4, FFAR1, FFAR4, FLT3, GPBAR1, GPR35, HPGD, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR4, HTR5A, HTR6, HTR7, IGF1R, INSR, KDR, MET, NMUR2, NPC1, NPSR1, PPARG, PTPRF, SIGMAR1, TSHR |
MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 2.650E-12 | 5.603E-10 | AR, ESRRA, NR1H4, NR1I2, NR3C1, NR3C2, PGR, PPARA, PPARD, PPARG, RORC |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 4.118E-12 | 8.302E-10 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, NOX4 |
MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 1.030E-11 | 1.869E-09 | AHR, AR, ESRRA, NR1H4, NR1I2, PGR, PPARA, PPARD, PPARG, RORC |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 7.510E-11 | 1.160E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
MF | GO:0005488; binding | GO:0020037; heme binding | 7.824E-11 | 1.184E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, MPO, NOX4, PTGS1, SRC |
BP | Unclassified; | GO:0032844; regulation of homeostatic process | 1.338E-10 | 1.905E-08 | ADRA2A, AURKB, CA2, CA7, DRD2, DRD3, HIF1A, HTR2A, HTR2B, HTR2C, KDR, MAPK1, NEK2, NPC1, NPSR1, NR1H4, PARP1, PLA2G1B, SRC, SYK, TNKS, TNKS2 |
MF | GO:0005488; binding | GO:0005496; steroid binding | 1.898E-10 | 2.607E-08 | AR, CYP3A4, ESRRA, HSD17B1, NPC1, NR1H4, NR3C1, NR3C2, PGR, RORC, SERPINA6 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.630E-10 | 3.449E-08 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 3.258E-10 | 4.173E-08 | CYP1A2, CYP2C19, CYP2C8, CYP2C9, CYP3A4, NR1I2 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 6.658E-10 | 8.010E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP2D6, CYP3A4 |
BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.110E-09 | 1.278E-07 | AURKB, CA2, CA7, DRD2, DRD3, HIF1A, MAPK1, NEK2, NPC1, NPSR1, NR1H4, PLA2G1B, SYK, TNKS, TNKS2 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.279E-09 | 1.465E-07 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, XDH |
BP | GO:0009987; cellular process | GO:0007198; adenylate cyclase-inhibiting serotonin receptor signaling pathway | 5.261E-09 | 5.255E-07 | HTR1A, HTR1B, HTR5A, HTR7 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 5.261E-09 | 5.255E-07 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 1.397E-08 | 1.269E-06 | AR, CDK1, ESRRA, NR1H4, NR1I2, NR3C1, NR3C2, PGR, PPARA, PPARD, PPARG, RORC |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.794E-08 | 1.608E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 3.329E-08 | 2.832E-06 | CYP1A2, CYP2C8, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0009987; cellular process | GO:0030168; platelet activation | 3.751E-08 | 3.117E-06 | ADRA2A, ADRA2B, ADRA2C, AKT1, AXL, MAPK1, PIK3CG, PIK3R1, SRC, SYK |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 7.461E-08 | 5.865E-06 | ABCC1, ADRA2A, CA2, CA4, CA9, HPGD, SLC22A1, SLC22A6, SLC22A8, SLCO1B1, SLCO1B3, TSHR |
BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 1.307E-07 | 9.781E-06 | ADRA2A, AKT1, FFAR1, HIF1A, INSR, NOX4, NR1H4, PIK3R1, PPARG, PTPN2, PYGL |
BP | GO:0048511; rhythmic process | GO:0042752; regulation of circadian rhythm | 1.683E-07 | 1.237E-05 | DRD2, DRD3, DRD4, PPARA, PPARG, RORC, TOP2A, TP53, USP2 |
BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 1.904E-07 | 1.373E-05 | AKT1, AURKB, CAMK2B, CDK1, GSK3B, MAPK1, NEK6, PKN1, SRC, SYK, TNKS |
BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 2.512E-07 | 1.753E-05 | AURKB, MAPK1, NEK2, TNKS, TNKS2 |
BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 2.522E-07 | 1.755E-05 | CA2, CA7, DRD2, DRD3, HTR2A, HTR2B, HTR2C, KDR, NPSR1, PARP1, PLA2G1B, SRC |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 2.771E-07 | 1.903E-05 | AHR, CSNK2A1, HIF1A, KDR, MAPT, NR3C1 |
BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 3.534E-07 | 2.346E-05 | AKT1, CAMK2B, CDK1, CSNK2A1, GSK3B, MAPK1, PKN1, TNKS |
MF | GO:0005488; binding | GO:0051379; epinephrine binding | 3.585E-07 | 2.373E-05 | ADRA2A, ADRA2B, ADRA2C, DRD4 |
MF | GO:0003824; catalytic activity | GO:0004674; protein serine/threonine kinase activity | 3.925E-07 | 2.551E-05 | AKT1, ALK, AURKB, CAMK2B, CDK1, CSNK2A1, DAPK1, GSK3B, MAPK1, MYLK, NEK2, NEK6, NUAK1, PIK3CG, PIM1, PKN1, SYK |
BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 4.055E-07 | 2.628E-05 | ADRA2A, ADRA2B, ADRA2C, AKT1, INSR, SRC |
BP | GO:0065007; biological regulation | GO:0000187; activation of MAPK activity | 4.480E-07 | 2.869E-05 | ADRA2B, ALK, CDK1, DRD4, INSR, MAPK1, PKN1, PLA2G1B, PTPN1, SYK |
MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 6.234E-07 | 3.912E-05 | ADRA2A, ADRA2B, ADRA2C |
MF | GO:0005488; binding | GO:0005524; ATP binding | 9.815E-07 | 5.888E-05 | ABCB1, ABCC1, ABCG2, AKT1, ALK, AURKB, AXL, CAMK2B, CDK1, CSNK2A1, DAPK1, FLT3, GSK3B, IGF1R, INSR, KDR, MAPK1, MET, MYLK, NEK2, NEK6, NUAK1, PIK3CG, PIM1, PKN1, PTK2, PYGL, RECQL, SRC, SYK, TOP2A, TP53 |
BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 1.032E-06 | 6.143E-05 | HPGD, HTR1B, MMP2, MMP9, TERT |
BP | GO:0051179; localization | GO:0042908; xenobiotic transport | 1.061E-06 | 6.211E-05 | ABCB1, ABCC1, ABCG2, NR1I2 |
BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 1.118E-06 | 6.519E-05 | ALOX15, APP, DRD2, FFAR4, HTR2A, HTR2B, HTR2C, KDR, NOX4, SRC, THPO |
BP | GO:0051179; localization | GO:0050482; arachidonic acid secretion | 1.310E-06 | 7.527E-05 | DRD2, DRD3, DRD4, NMUR2, PLA2G1B |
BP | GO:0009987; cellular process | GO:0002031; G-protein coupled receptor internalization | 1.656E-06 | 9.201E-05 | DRD2, DRD3, HTR1B, HTR2B |
BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 2.478E-06 | 1.339E-04 | ADRA2A, ADRA2B, ADRA2C |
BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 2.478E-06 | 1.339E-04 | ADRA2A, ADRA2B, ADRA2C |
CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 2.500E-06 | 1.345E-04 | AHR, AKR1B1, AKT1, ALOX5, APEX1, AR, AURKB, BRCA1, CAMK2B, CDC25B, CDK1, CSNK2A1, CTDSP1, ESRRA, FABP5, GSK3B, HDAC3, HIF1A, HPGD, L3MBTL1, LMNA, MAPK1, NEK2, NEK6, NFKB1, NR1H4, NR1I2, NR3C1, NR3C2, NUAK1, PARP1, PGR, PIM1, PKN1, POLB, PPARA, PPARD, PPARG, PTPN2, RECQL, RORC, SMN1, SMN2, SRC, STAT6, TERT, TNKS, TOP2A, TP53, USP2 |
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 2.952E-06 | 1.556E-04 | IGF1R, INSR, KDR, PTK2, SRC, SYK |
BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 3.086E-06 | 1.608E-04 | CTSD, MMP1, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 3.709E-06 | 1.896E-04 | CTSD, HIF1A, MMP1, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
BP | Unclassified; | GO:0032845; negative regulation of homeostatic process | 4.342E-06 | 2.163E-04 | ADRA2A, DRD2, HTR2A, HTR2B, HTR2C, PARP1, SRC, TNKS, TNKS2 |
BP | GO:0008152; metabolic process | GO:0010513; positive regulation of phosphatidylinositol biosynthetic process | 6.155E-06 | 2.849E-04 | HTR2A, HTR2B, HTR2C |
BP | GO:0009987; cellular process | GO:0050714; positive regulation of protein secretion | 6.163E-06 | 2.849E-04 | ACHE, DRD2, FFAR1, HIF1A, HTR2B, NR1H4, PLA2G1B, PPARD, SRC, SYK, TLR2 |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 6.155E-06 | 2.849E-04 | CYP1A1, CYP2C8, CYP3A4 |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 6.754E-06 | 3.096E-04 | AXL, INSR, MET, NOX4, PIK3CG, PIK3R1, PTK2, SRC, THPO |
BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 6.813E-06 | 3.117E-04 | CYP19A1, FFAR4, NFKB1, NR1H4, PPARA, PPARD, PPARG, PTPN2 |
BP | GO:0050896; response to stimulus | GO:0045471; response to ethanol | 7.265E-06 | 3.290E-04 | CA3, CDK1, DRD3, HPGD, HTR1B, HTR3A, POLB, TP53 |
BP | GO:0032501; multicellular organismal process | GO:0032922; circadian regulation of gene expression | 7.529E-06 | 3.394E-04 | AHR, DRD2, DRD3, PPARA, RORC, USP2 |
BP | GO:0008152; metabolic process | GO:0010907; positive regulation of glucose metabolic process | 8.621E-06 | 3.839E-04 | AKT1, INSR, PPARA, PTPN2, SRC |
BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 8.833E-06 | 3.917E-04 | ALOX12, ALOX15, ALOX5, HPGD |
BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 9.268E-06 | 4.085E-04 | CTSD, HIF1A, MMP1, MMP13, MMP2, MMP3, MMP9 |
BP | GO:0065007; biological regulation | GO:0032212; positive regulation of telomere maintenance via telomerase | 1.004E-05 | 4.380E-04 | AURKB, MAPK1, NEK2, TNKS, TNKS2 |
BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 1.223E-05 | 5.243E-04 | CYP1A1, CYP2C8, CYP3A4 |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 1.382E-05 | 5.810E-04 | AKR1B1, APEX1, AXL, CDK1, CYP1B1, STAT6 |
BP | GO:0008152; metabolic process | GO:0051000; positive regulation of nitric-oxide synthase activity | 1.465E-05 | 6.066E-04 | AKT1, HIF1A, HTR2B, TERT |
MF | GO:0005488; binding | GO:0042803; protein homodimerization activity | 1.678E-05 | 6.854E-04 | ABCG2, ACHE, ADRA2A, ADRA2C, AKT1, APOBEC3G, CAMK2B, DRD2, FLT3, GLA, HPGD, MAPT, NFKB1, PYGL, SLC22A1, SLC22A6, TERT, TOP2A, TYR, XDH |
BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 1.999E-05 | 8.020E-04 | CTSD, MMP1, MMP13, MMP2, MMP3, MMP9 |
MF | GO:0005215; transporter activity | GO:0008559; xenobiotic transmembrane transporting ATPase activity | 2.127E-05 | 8.452E-04 | ABCB1, ABCC1, ABCG2 |
BP | GO:0051179; localization | GO:0042307; positive regulation of protein import into nucleus | 2.189E-05 | 8.681E-04 | APP, CDK1, HDAC3, MAPK1, PARP1, PIK3R1, TLR2 |
BP | GO:0007610; behavior | GO:0048148; behavioral response to cocaine | 2.289E-05 | 9.003E-04 | DRD2, DRD3, DRD4, HTR2A |
BP | GO:0009987; cellular process | GO:0071880; adenylate cyclase-activating adrenergic receptor signaling pathway | 2.289E-05 | 9.003E-04 | ADRA2A, ADRA2B, ADRA2C, DRD2 |
BP | GO:0050896; response to stimulus | GO:0009611; response to wounding | 2.506E-05 | 9.660E-04 | ACHE, ADORA3, ALOX15, CDK1, CYP1A1, DRD2, PPARA, PPARD, TP53 |
BP | GO:0007610; behavior | GO:0007626; locomotory behavior | 2.506E-05 | 9.660E-04 | ALK, APP, DRD2, DRD3, DRD4, GAA, HTR2C, NPC1, USP2 |
CC | GO:0044464; cell part | GO:0005764; lysosome | 2.591E-05 | 9.915E-04 | AKR1B1, AKR1B10, CTSD, GAA, GLA, MPO, NPC1, PIK3CG, RAB9A, SRC, TYR |
BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 2.809E-05 | 1.061E-03 | CYP1A1, POLB, PPARG, TP53 |
BP | GO:0009987; cellular process | GO:2001237; negative regulation of extrinsic apoptotic signaling pathway | 3.025E-05 | 1.136E-03 | AKT1, AR, BRCA1, DAPK1, LMNA, SRC, TERT |
BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 3.220E-05 | 1.203E-03 | AKT1, HIF1A, LMNA, PPARD, SRC, TERT, TP53 |
BP | GO:0051179; localization | GO:0046326; positive regulation of glucose import | 3.262E-05 | 1.212E-03 | AKT1, INSR, NR1H4, PIK3R1, TERT |
BP | GO:0009987; cellular process | GO:0010700; negative regulation of norepinephrine secretion | 3.382E-05 | 1.246E-03 | ADRA2A, ADRA2B, ADRA2C |
MF | GO:0060089; molecular transducer activity | GO:0001591; dopamine neurotransmitter receptor activity, coupled via Gi/Go | 3.382E-05 | 1.246E-03 | DRD2, DRD3, DRD4 |
MF | GO:0005215; transporter activity | GO:0015347; sodium-independent organic anion transmembrane transporter activity | 4.888E-05 | 1.722E-03 | SLC22A6, SLC22A8, SLCO1B1, SLCO1B3 |
MF | GO:0005488; binding | GO:0032052; bile acid binding | 5.041E-05 | 1.764E-03 | NR1H4, PLA2G1B, PYGL |
MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 5.041E-05 | 1.764E-03 | INSR, KDR, SYK |
MF | Unclassified; | GO:0032403; protein complex binding | 5.530E-05 | 1.927E-03 | ACHE, ADRA2A, APEX1, FLT3, HTR2A, IGF1R, INSR, KDR, MMP13, MMP9, PIK3R1, PPARA, PTPN1, PTPN2, PTPRF, SRC, SYK, TLR2, TSHR |
BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 5.780E-05 | 2.007E-03 | FABP2, FABP3, FABP4, FABP5 |
BP | GO:0002376; immune system process | GO:0002682; regulation of immune system process | 6.013E-05 | 2.075E-03 | AHR, AKT1, ALOX15, APOBEC3G, APP, AXL, CA2, CYP19A1, DRD2, ESRRA, HIF1A, L3MBTL1, MAPK1, MMP2, NFKB1, NR1H4, PIK3R1, PKN1, PLA2G1B, PPARG, PTK2, PTPN1, PTPN2, SRC, STAT6, SYK, THPO, TLR2, TP53 |
BP | GO:0050896; response to stimulus | GO:0046626; regulation of insulin receptor signaling pathway | 6.199E-05 | 2.133E-03 | NR1H4, PIK3R1, PTPN1, PTPN2, SRC |
BP | GO:0050896; response to stimulus | GO:1901655; cellular response to ketone | 7.012E-05 | 2.371E-03 | AKR1B1, AKT1, AR, NR3C1, PPARG, SRC |
BP | GO:0009987; cellular process | GO:0007195; adenylate cyclase-inhibiting dopamine receptor signaling pathway | 7.156E-05 | 2.405E-03 | DRD2, DRD3, DRD4 |
BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 7.156E-05 | 2.405E-03 | ABCB1, CA2, CA7 |
BP | GO:0008152; metabolic process | GO:0051974; negative regulation of telomerase activity | 7.156E-05 | 2.405E-03 | PPARG, SRC, TP53 |
BP | GO:0009987; cellular process | GO:0007208; phospholipase C-activating serotonin receptor signaling pathway | 7.341E-05 | 2.437E-03 | HTR2A, HTR2C |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 7.341E-05 | 2.437E-03 | APEX1, POLB |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 7.341E-05 | 2.437E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 7.341E-05 | 2.437E-03 | ALOX12, ALOX15 |
MF | GO:0005488; binding | GO:0071886; 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding | 7.341E-05 | 2.437E-03 | HTR2A, HTR2C |
BP | GO:0032501; multicellular organismal process | GO:0051241; negative regulation of multicellular organismal process | 7.526E-05 | 2.491E-03 | ADRA2C, ALOX12, APP, AXL, CTDSP1, DRD2, DRD3, FFAR4, GPR35, GSK3B, HIF1A, LMNA, NFKB1, NR1H4, PIK3CG, PIK3R1, PPARD, PPARG, PTK2, PTPN2, TERT, TLR2, XDH |
BP | GO:0065007; biological regulation | GO:1904357; negative regulation of telomere maintenance via telomere lengthening | 7.912E-05 | 2.595E-03 | PARP1, SRC, TNKS, TNKS2 |
BP | GO:0050896; response to stimulus | GO:1904646; cellular response to amyloid-beta | 7.912E-05 | 2.595E-03 | APP, GSK3B, IGF1R, PARP1 |
MF | GO:0003824; catalytic activity | GO:0033764; steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | 7.912E-05 | 2.595E-03 | HSD11B1, HSD17B1, HSD17B10, HSD17B2 |
BP | GO:0008152; metabolic process | GO:0046320; regulation of fatty acid oxidation | 9.169E-05 | 2.923E-03 | AKT1, FABP3, PPARA, PPARG |
BP | GO:0008152; metabolic process | GO:0042417; dopamine metabolic process | 9.169E-05 | 2.923E-03 | DRD2, DRD3, DRD4, MAOA |
BP | GO:0051179; localization | GO:0043252; sodium-independent organic anion transport | 9.169E-05 | 2.923E-03 | SLC22A6, SLC22A8, SLCO1B1, SLCO1B3 |
BP | GO:0009987; cellular process | GO:0014059; regulation of dopamine secretion | 9.169E-05 | 2.923E-03 | DRD2, DRD3, HTR1B, HTR2A |
MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 9.169E-05 | 2.923E-03 | AKT1, MAPT, PTPN1, TP53 |
MF | GO:0005488; binding | GO:0051059; NF-kappaB binding | 9.169E-05 | 2.923E-03 | APEX1, GSK3B, HDAC3, PPARD |
BP | GO:0050896; response to stimulus | GO:0034776; response to histamine | 9.777E-05 | 3.094E-03 | DRD2, DRD3, DRD4 |
MF | GO:0005488; binding | GO:0043560; insulin receptor substrate binding | 9.777E-05 | 3.094E-03 | IGF1R, INSR, PIK3R1 |
BP | GO:0002376; immune system process | GO:0048534; hematopoietic or lymphoid organ development | 1.000E-04 | 3.156E-03 | FLT3, HIF1A, KDR, L3MBTL1, MAPK1, PKN1, POLB, TYR |
MF | GO:0005488; binding | GO:0046982; protein heterodimerization activity | 1.031E-04 | 3.235E-03 | ADRA2A, ADRA2C, AHR, AXL, DRD2, HIF1A, NFKB1, PIK3R1, PPARD, PPARG, TLR2, TOP2A, TP53, TYR |
MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 1.057E-04 | 3.282E-03 | AXL, IGF1R, INSR, PIK3R1 |
CC | GO:0032991; macromolecular complex | GO:0043235; receptor complex | 1.108E-04 | 3.418E-03 | ABCG2, ADRA2A, AHR, APP, HTR3A, IGF1R, INSR, NR3C2, SYK, TLR2, TSHR |
BP | GO:0051179; localization | GO:0030100; regulation of endocytosis | 1.194E-04 | 3.637E-03 | ALOX15, APP, AXL, DRD2, PPARG, PTPN1, SRC, SYK, TLR2 |
BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 1.262E-04 | 3.807E-03 | AKT1, INSR, MAPT, NOX4, TP53, XDH |
BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 1.381E-04 | 4.086E-03 | AKT1, CYP1A2, MAPK1, MMP9 |
CC | GO:0044464; cell part | GO:0005829; cytosol | 1.374E-04 | 4.086E-03 | ACP1, AHR, AKR1B1, AKR1B10, AKT1, ALDH1A1, ALOX12, ALOX15, ALOX5, APOBEC3G, APP, AR, AURKB, CA1, CA2, CA3, CA7, CAMK2B, CDC25B, CDK1, CSNK2A1, FABP2, FABP3, FABP4, FABP5, FLT3, GLO1, GSK3B, HDAC3, HIF1A, HPGD, HSD17B1, HTR2A, LMNA, MAPK1, MAPT, MYLK, NEK2, NEK6, NFKB1, NR3C1, NR3C2, PGR, PIK3CG, PIK3R1, PIM1, PKN1, PLA2G1B, PPARG, PTK2, PTPN1, PTPN2, PYGL, RAB9A, SMN1, SMN2, SRC, STAT6, SYK, TNKS, TNKS2, TP53, TYR, XDH |
BP | GO:0009987; cellular process | GO:1901214; regulation of neuron death | 1.502E-04 | 4.409E-03 | AKT1, AXL, GSK3B, HIF1A, MAPT, PARP1, PPARA, SIGMAR1, TERT, TP53 |
BP | GO:0009987; cellular process | GO:0045600; positive regulation of fat cell differentiation | 1.519E-04 | 4.445E-03 | AKT1, HTR2A, HTR2C, PPARD, PPARG |
BP | GO:0065007; biological regulation | GO:0007194; negative regulation of adenylate cyclase activity | 1.568E-04 | 4.558E-03 | ADRA2A, DRD2, DRD3, DRD4 |
BP | GO:0023052; signaling | GO:0032228; regulation of synaptic transmission, GABAergic | 1.568E-04 | 4.558E-03 | CA2, CA7, DRD2, HTR1B |
BP | GO:0032501; multicellular organismal process | GO:0003007; heart morphogenesis | 1.568E-04 | 4.558E-03 | GAA, HTR2B, INSR, PTK2 |
BP | GO:0008152; metabolic process | GO:0031331; positive regulation of cellular catabolic process | 1.629E-04 | 4.710E-03 | ADRA2A, AKT1, CDK1, DAPK1, GSK3B, HIF1A, HTR2A, INSR, KDR, PPARA, PTK2, PTPN1 |
BP | Unclassified; | GO:0019229; regulation of vasoconstriction | 1.645E-04 | 4.752E-03 | ADRA2A, ADRA2B, ADRA2C, AKT1, HTR2A |
BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 1.673E-04 | 4.813E-03 | CYP19A1, HSD17B1, HSD17B2 |
BP | GO:0009987; cellular process | GO:1900103; positive regulation of endoplasmic reticulum unfolded protein response | 1.673E-04 | 4.813E-03 | PIK3R1, PTPN1, PTPN2 |
MF | GO:0005488; binding | GO:0035240; dopamine binding | 1.673E-04 | 4.813E-03 | DRD2, DRD3, DRD4 |
BP | GO:0008152; metabolic process | GO:1903580; positive regulation of ATP metabolic process | 1.995E-04 | 5.627E-03 | CDK1, HIF1A, HTR2A, INSR |
BP | GO:0032501; multicellular organismal process | GO:0045685; regulation of glial cell differentiation | 2.074E-04 | 5.813E-03 | APP, CDK1, DRD3, PPARG, TLR2 |
BP | GO:0023052; signaling | GO:0051967; negative regulation of synaptic transmission, glutamatergic | 2.116E-04 | 5.893E-03 | DRD2, HTR1B, HTR2A |
BP | GO:0032501; multicellular organismal process | GO:0014005; microglia development | 2.190E-04 | 5.991E-03 | APP, TLR2 |
BP | GO:0022414; reproductive process | GO:0060748; tertiary branching involved in mammary gland duct morphogenesis | 2.190E-04 | 5.991E-03 | AR, PGR |
BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 2.190E-04 | 5.991E-03 | CYP2D6, CYP3A4 |
BP | GO:0051179; localization | GO:0099039; sphingolipid translocation | 2.190E-04 | 5.991E-03 | ABCB1, ABCC1 |
BP | GO:0009987; cellular process | GO:0060160; negative regulation of dopamine receptor signaling pathway | 2.190E-04 | 5.991E-03 | DRD2, DRD3 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.190E-04 | 5.991E-03 | CA2, CA7 |
BP | GO:0023052; signaling | GO:0051586; positive regulation of dopamine uptake involved in synaptic transmission | 2.190E-04 | 5.991E-03 | DRD2, DRD4 |
BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 2.190E-04 | 5.991E-03 | GPBAR1, NR1H4 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 2.190E-04 | 5.991E-03 | CYP1A1, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 2.190E-04 | 5.991E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 2.190E-04 | 5.991E-03 | ALOX12, ALOX15 |
MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 2.190E-04 | 5.991E-03 | GPBAR1, NR1H4 |
BP | GO:0051179; localization | GO:0006855; drug transmembrane transport | 2.235E-04 | 6.090E-03 | ABCB1, ABCC1, ABCG2, SLC22A1, SLC22A3 |
BP | GO:0008283; cell proliferation | GO:2000648; positive regulation of stem cell proliferation | 2.238E-04 | 6.090E-03 | DRD2, HIF1A, TERT, THPO |
MF | GO:0140110; transcription regulator activity | GO:0001228; transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding | 2.244E-04 | 6.101E-03 | AR, ESRRA, HIF1A, NFKB1, NR1H4, NR1I2, NR3C1, PARP1, PGR, PPARA, STAT6, TP53 |
MF | GO:0005215; transporter activity | GO:0005319; lipid transporter activity | 2.500E-04 | 6.695E-03 | ABCB1, ABCC1, ABCG2, FABP3, NPC1, SLCO1B1, SLCO1B3 |
BP | GO:0051179; localization | GO:0070198; protein localization to chromosome, telomeric region | 2.629E-04 | 6.998E-03 | TERT, TNKS, TNKS2 |
BP | GO:0040011; locomotion | GO:0014910; regulation of smooth muscle cell migration | 2.772E-04 | 7.333E-03 | APEX1, NOX4, PPARD, SRC, TERT |
BP | GO:0065007; biological regulation | GO:0008217; regulation of blood pressure | 3.079E-04 | 8.058E-03 | ADRA2B, AR, DRD2, DRD3, PPARA, PPARG, PTGS1 |
BP | GO:0051179; localization | GO:0032368; regulation of lipid transport | 3.250E-04 | 8.446E-03 | AKT1, CYP19A1, NFKB1, PPARA, PPARG, SYK |
BP | GO:0009987; cellular process | GO:1901992; positive regulation of mitotic cell cycle phase transition | 3.403E-04 | 8.822E-03 | APEX1, APP, CDK1, CYP1A1, TERT |
MF | GO:0005488; binding | GO:0042826; histone deacetylase binding | 3.417E-04 | 8.840E-03 | HDAC3, HIF1A, PARP1, PKN1, TOP2A, TP53 |
CC | GO:0016020; membrane | GO:0005901; caveola | 3.636E-04 | 9.358E-03 | HTR2A, INSR, MAPK1, SLC22A6, SRC |
CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 3.667E-04 | 9.417E-03 | CAMK2B, CDK1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, FAAH, HSD11B1, HSD17B2, NOX4, NR3C2, PTGS1, RAB9A, SIGMAR1 |
BP | GO:0022610; biological adhesion | GO:0033628; regulation of cell adhesion mediated by integrin | 3.777E-04 | 9.665E-03 | CYP1B1, PIK3CG, PTK2, SYK |
BP | GO:0008283; cell proliferation | GO:0008285; negative regulation of cell proliferation | 3.845E-04 | 9.825E-03 | ADORA3, APP, AR, CYP1B1, DRD2, FABP3, LMNA, NOX4, PKN1, PPARD, PPARG, PTPN2, TERT, TLR2, TP53, XDH |
BP | GO:0008152; metabolic process | GO:0046209; nitric oxide metabolic process | 3.879E-04 | 9.825E-03 | AKT1, CYP1B1, TLR2 |
BP | GO:0050896; response to stimulus | GO:0033189; response to vitamin A | 3.879E-04 | 9.825E-03 | CYP1A1, PPARD, PPARG |
BP | GO:0051179; localization | GO:1901386; negative regulation of voltage-gated calcium channel activity | 3.879E-04 | 9.825E-03 | DRD2, DRD4, GPR35 |
BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 3.880E-04 | 9.825E-03 | AXL, KDR, PIK3R1, PTK2, SRC |
MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 3.879E-04 | 9.825E-03 | CYP2C19, CYP2C8, CYP2C9 |
MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 3.879E-04 | 9.825E-03 | AURKB, CDK1, PKN1 |
CC | GO:0044464; cell part | GO:0030424; axon | 3.919E-04 | 9.900E-03 | ADRA2C, APP, BACE1, CA2, DRD2, HTR2A, HTR3A, MAPK1, MAPT |
MF | GO:0005488; binding | GO:0051378; serotonin binding | 1.350E-23 | 4.199E-20 | HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR5A, HTR7 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.789E-20 | 3.030E-17 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
BP | GO:0009987; cellular process | GO:0007210; serotonin receptor signaling pathway | 2.682E-19 | 3.074E-16 | HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR4, HTR5A, HTR6, HTR7 |
MF | GO:0060089; molecular transducer activity | GO:0004993; G-protein coupled serotonin receptor activity | 2.682E-19 | 3.074E-16 | HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR4, HTR5A, HTR6, HTR7 |
MF | Unclassified; | GO:0004872; receptor activity | 2.839E-18 | 2.472E-15 | ADORA3, ADRA2A, ADRA2B, ADRA2C, AHR, ALK, AR, AXL, CXCR1, DRD2, DRD3, DRD4, ESRRA, FFAR1, FFAR4, FLT3, GPBAR1, GPR35, HPGD, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR4, HTR5A, HTR6, HTR7, IGF1R, INSR, KDR, MET, NMUR2, NPC1, NPSR1, NR1H4, NR1I2, NR3C1, NR3C2, PGR, PPARA, PPARD, PPARG, PTPRF, RORC, SIGMAR1, TLR2, TSHR |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.173E-14 | 4.817E-12 | APOBEC3G, AR, BRCA1, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESRRA, GLO1, L3MBTL1, MMP1, MMP13, MMP2, MMP3, MMP9, NR1H4, NR1I2, NR3C1, NR3C2, PARP1, PGR, PPARA, PPARD, PPARG, PTPN1, RORC, TNKS, TP53 |
CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 2.686E-14 | 9.587E-12 | ABCC1, ADORA3, ADRA2A, ADRA2B, ADRA2C, ALK, APP, AXL, BACE1, DRD2, DRD3, DRD4, FFAR1, FFAR4, FLT3, GPR35, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR4, HTR5A, HTR6, HTR7, IGF1R, INSR, KDR, MET, NPC1, NPSR1, PTPRF, SIGMAR1, SLC22A1, SLC22A3, SLC22A6, SLC22A8, SLCO1B1, SLCO1B3, TLR2, TSHR |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 8.113E-14 | 2.454E-11 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.506E-13 | 9.198E-11 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.894E-27 | 3.675E-25 | APP; HTR1E; HTR1F; MAOA; HTR1D; ALOX15; HTR1A; HTR2B; HTR1B; HTR2C; ALOX12; HTR3A; HTR2A; HTR5A; CYP2C19; HTR4; PTGS1; CYP2C9; CYP2C8; HTR6; HTR7; CYP2D6; ALOX5; MAPK1 |
hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 1.107E-16 | 7.159E-15 | HTR1E; GPR35; HTR1F; HTR1D; HTR1A; HTR2B; HTR1B; HTR2C; HTR2A; HTR5A; HTR4; ADRA2C; NR3C1; ADRA2B; ADRA2A; TSHR; HTR6; HTR7; ADORA3; NMUR2; DRD2; DRD3; DRD4 |
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.091E-19 | 1.059E-17 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.026E-11 | 4.976E-10 | CAMK2B; HTR1E; HTR1F; HTR1D; HTR1A; HTR1B; PIK3R1; HTR4; NFKB1; TSHR; PIK3CG; HTR6; AKT1; MAPK1; PPARA; DRD2 |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.548E-10 | 6.006E-09 | CAMK2B; SRC; MMP2; PIK3R1; HIF1A; MMP9; PTK2; PIK3CG; IGF1R; KDR; AKT1; MAPK1; TP53; MET; TLR2 |
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 8.821E-10 | 2.852E-08 | GSK3B; FLT3; MMP1; DAPK1; MMP2; PIK3R1; HIF1A; MMP9; NFKB1; PIK3CG; PTK2; IGF1R; AR; AKT1; MAPK1; PPARG; MET; TP53; PPARD |
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 7.590E-09 | 1.636E-07 | HSD17B1; ALOX5; INSR; HSD17B2; CYP1A1; CYP1B1; CYP19A1; IGF1R |
hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 2.679E-08 | 3.712E-07 | GSK3B; SYK; INSR; PIK3R1; BRCA1; PTK2; NFKB1; PIK3CG; IGF1R; KDR; AKT1; MAPK1; PKN1; TP53; MET; TLR2 |
hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 1.047E-08 | 2.032E-07 | PTPN1; CSNK2A1; SRC; INSR; MAPK1; ACP1; MET; PTPRF; IGF1R |
hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 2.224E-08 | 3.712E-07 | FLT3; PIM1; AKT1; MAPK1; PIK3R1; NFKB1; PIK3CG; PPARD |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 7.208E-09 | 1.636E-07 | SLCO1B1; ABCB1; CA2; SLCO1B3; SLC22A1; NR1H4; SLC22A8; CYP3A4; ABCG2 |
hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 2.487E-08 | 3.712E-07 | PTPN1; GSK3B; INSR; AKT1; PIK3R1; PYGL; PPARA; NFKB1; PTPRF; PIK3CG |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 3.199E-09 | 8.866E-08 | CYP2C9; CYP2C8; PLA2G1B; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 5.416E-08 | 6.181E-07 | GSK3B; AR; AKT1; MAPK1; PIK3R1; TP53; NFKB1; PIK3CG; IGF1R |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 4.393E-08 | 5.327E-07 | CYP2C9; CYP2C8; PLA2G1B; ALOX5; ALOX15; ALOX12; CYP2C19; PTGS1 |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.562E-08 | 3.712E-07 | HSD11B1; HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 8.182E-08 | 8.818E-07 | FLT3; AKT1; MAPK1; PIK3R1; TP53; MET; HIF1A; PIK3CG |
hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.937E-07 | 1.879E-06 | CAMK2B; INSR; AKT1; MAPK1; PIK3R1; HIF1A; NFKB1; PIK3CG; IGF1R |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 4.238E-08 | 5.327E-07 | MMP1; DAPK1; SRC; MMP2; MAPK1; MMP9; TP53 |
hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 3.968E-07 | 3.252E-06 | SRC; AKT1; MAPK1; STAT6; PIK3R1; TP53; MMP9; NFKB1; PIK3CG; TLR2 |
hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 3.253E-07 | 3.005E-06 | HPGD; FLT3; MMP3; PPARG; TP53; MPO; MMP9; MET; NFKB1; PTK2; IGF1R |
hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 1.034E-07 | 1.056E-06 | FABP2; FABP3; FABP4; FABP5; MMP1; PPARG; PPARA; PPARD |
hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 6.206E-07 | 4.752E-06 | GSK3B; HDAC3; SRC; AKT1; MAPK1; PIK3R1; TP53; HIF1A; PIK3CG |
hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 1.024E-06 | 6.847E-06 | GSK3B; SRC; KDR; AKT1; MAPK1; PIK3R1; MET; PTK2; PIK3CG; MYLK; IGF1R |
hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 3.938E-07 | 3.252E-06 | FABP4; INSR; AKT1; PIK3R1; TSHR; PIK3CG; PTGS1 |
hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 6.369E-07 | 4.752E-06 | CAMK2B; GSK3B; SRC; AKT1; MAPK1; PIK3R1; PTK2; PIK3CG |
hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 1.365E-06 | 8.273E-06 | ADORA3; INSR; AKT1; MAPK1; PIK3R1; ADRA2C; ADRA2B; ADRA2A; PIK3CG; MYLK |
hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 7.156E-07 | 4.958E-06 | ABCC1; ADORA3; AKT1; MAPK1; PIK3R1; TP53; CTSD; NFKB1; PIK3CG |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 4.024E-07 | 3.252E-06 | HSD11B1; CYP2C9; CYP2C8; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 7.155E-07 | 4.958E-06 | SRC; KDR; AKT1; MAPK1; PIK3R1; PTK2; PIK3CG |
hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 1.588E-06 | 9.060E-06 | CAMK2B; SRC; HTR2B; HTR2C; ALOX12; PIK3R1; HTR2A; PIK3CG |
hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 1.155E-06 | 7.229E-06 | INSR; AKT1; PPARG; PIK3R1; TP53; NFKB1; PIK3CG; IGF1R |
hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.110E-06 | 7.181E-06 | CAMK2B; AKT1; MAPK1; PIK3R1; TP53; PIK3CG; IGF1R |
hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 1.588E-06 | 9.060E-06 | CDK1; AKT1; MAPK1; PGR; PIK3R1; PIK3CG; CDC25B; IGF1R |
hsa05162 | Measles_Homo sapiens_hsa05162 | 2.046E-06 | 1.073E-05 | GSK3B; CSNK2A1; AKT1; RAB9A; PIK3R1; TP53; NFKB1; PIK3CG; TLR2 |
hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 3.189E-06 | 1.439E-05 | HTR7; PLA2G1B; INSR; KDR; AKT1; MAPK1; PIK3R1; MET; NFKB1; PIK3CG; IGF1R |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 2.602E-06 | 1.202E-05 | PARP1; LMNA; AKT1; MAPK1; PIK3R1; TP53; CTSD; NFKB1; PIK3CG |
hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 2.452E-06 | 1.163E-05 | PTPN1; GSK3B; INSR; AKT1; MAPK1; PIK3R1; PYGL; PTPRF; PIK3CG |
hsa05218 | Melanoma_Homo sapiens_hsa05218 | 2.035E-06 | 1.073E-05 | AKT1; MAPK1; PIK3R1; TP53; MET; PIK3CG; IGF1R |
hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 2.238E-06 | 1.143E-05 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; NFKB1; PIK3CG |
hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 8.527E-06 | 3.417E-05 | POLB; HDAC3; SYK; SRC; CDK1; MAPK1; PIK3R1; TP53; NFKB1; PIK3CG |
hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 2.458E-06 | 1.163E-05 | GSK3B; SYK; AKT1; MAPK1; PIK3R1; NFKB1; PIK3CG |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.674E-06 | 9.277E-06 | CYP2C9; CYP2C8; MAOA; CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 1.097E-05 | 4.258E-05 | SRC; INSR; KDR; AKT1; MAPK1; PIK3R1; DRD2; MET; PIK3CG; IGF1R |
hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 8.210E-06 | 3.389E-05 | SYK; SRC; AKT1; MAPK1; PIK3R1; PIK3CG; MYLK; PTGS1 |
hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 7.266E-06 | 3.064E-05 | CAMK2B; GSK3B; AKT1; MAPK1; PIK3R1; TP53; NFKB1; PIK3CG |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 2.458E-06 | 1.163E-05 | HSD11B1; CYP2C9; CYP2D6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.547E-05 | 5.770E-05 | GSK3B; AKT1; MAPK1; PIK3R1; PPARA; TP53; NFKB1; PIK3CG |
hsa04020 | Calcium signaling pathway_Homo sapiens_hsa04020 | 1.999E-05 | 6.685E-05 | CAMK2B; HTR6; HTR7; HTR2B; HTR2C; HTR2A; HTR5A; HTR4; MYLK |
hsa04540 | Gap junction_Homo sapiens_hsa04540 | 8.631E-06 | 3.417E-05 | SRC; CDK1; HTR2B; HTR2C; MAPK1; HTR2A; DRD2 |
hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 2.137E-05 | 6.908E-05 | MMP2; PIM1; AKT1; MAPK1; PIK3R1; NFKB1; PIK3CG |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 3.954E-05 | 1.198E-04 | ABCC1; ABCB1; PIM1; CYP1B1; MAPK1; BRCA1; TP53; MMP9; MET; NFKB1; CDC25B |
hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 2.703E-05 | 8.595E-05 | GSK3B; CXCR1; SRC; AKT1; MAPK1; PIK3R1; NFKB1; PTK2; PIK3CG |
hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.875E-05 | 6.382E-05 | SRC; MMP2; AKT1; MAPK1; PIK3R1; MMP9; PIK3CG |
hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 4.941E-05 | 1.475E-04 | GSK3B; SYK; CSNK2A1; CDK1; AKT1; PIK3R1; TP53; NFKB1; PIK3CG |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 9.112E-05 | 2.562E-04 | PLA2G1B; MAOA; GAA; ALOX15; AKR1B1; ALOX12; PYGL; CYP2C19; CYP3A4; TYR; CYP19A1; HSD17B10; PTGS1; HSD11B1; CYP2C9; CYP2C8; AKR1B10; HSD17B1; ALOX5; HSD17B2; CYP1A2; ALDH1A1; CYP1A1; XDH |
hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 2.137E-05 | 6.908E-05 | SLC22A3; SLC22A1; AKT1; MAPK1; PIK3R1; HIF1A; PIK3CG |
hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 6.878E-06 | 2.965E-05 | ALK; AKT1; MAPK1; PIK3R1; TP53; PIK3CG |
hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 3.714E-05 | 1.144E-04 | MMP3; AKT1; MAPK1; PIK3R1; MMP9; NFKB1; PIK3CG |
hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 4.433E-06 | 1.954E-05 | GSK3B; AKT1; MAPK1; PIK3R1; TP53; PIK3CG |
hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 5.822E-05 | 1.711E-04 | ALOX5; AKT1; MAPK1; PIK3R1; NFKB1; PIK3CG; TLR2 |
hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 1.023E-04 | 2.834E-04 | CAMK2B; GSK3B; MAOA; AKT1; DRD2; DRD3; DRD4 |
hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 1.228E-04 | 3.263E-04 | CAMK2B; SYK; SRC; AKT1; MAPK1; CTSD; NFKB1; TLR2 |
hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.250E-05 | 4.755E-05 | GSK3B; AKT1; MAPK1; PIK3R1; TP53; PIK3CG |
hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 1.181E-04 | 3.183E-04 | SYK; AKT1; MAPK1; PPARG; PIK3R1; NFKB1; PIK3CG |
hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.798E-05 | 6.227E-05 | AKT1; MAPK1; PIK3R1; TP53; NFKB1; PIK3CG |
hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 2.027E-04 | 5.173E-04 | SYK; CXCR1; INSR; AKT1; MAPK1; PIK3R1; PIK3CG |
hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.798E-05 | 6.227E-05 | AKT1; MAPK1; PIK3R1; MET; HIF1A; PIK3CG |
hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 3.210E-05 | 1.005E-04 | AKT1; MAPK1; PIK3R1; TP53; NFKB1; PIK3CG |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.645E-05 | 6.023E-05 | CYP2C9; CYP2C8; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 2.711E-04 | 6.492E-04 | GSK3B; INSR; AKT1; PIK3R1; PPARA; NFKB1; PIK3CG |
hsa04742 | Taste transduction_Homo sapiens_hsa04742 | 6.649E-05 | 1.925E-04 | HTR1E; HTR1F; HTR1D; HTR1A; HTR1B; HTR3A |
hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 3.570E-04 | 8.244E-04 | THPO; PIM1; AKT1; STAT6; PIK3R1; PTPN2; PIK3CG |
hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 8.114E-05 | 2.315E-04 | AKT1; PIK3R1; TP53; NFKB1; PTK2; PIK3CG |
hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 2.316E-04 | 5.761E-04 | AKT1; MAPK1; PIK3R1; NFKB1; PIK3CG; TLR2 |
hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 3.296E-04 | 7.745E-04 | CAMK2B; ACHE; AKT1; MAPK1; PIK3R1; PIK3CG |
hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 2.569E-04 | 6.230E-04 | AKT1; MAPK1; PIK3R1; NFKB1; PIK3CG; TLR2 |
hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 2.316E-04 | 5.761E-04 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1; PIK3CG |
hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 1.440E-03 | 3.004E-03 | POLB; GSK3B; TERT; AKT1; PIK3R1; TP53; NFKB1; PIK3CG |
hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 5.701E-04 | 1.286E-03 | CAMK2B; AR; CDK1; MAPK1; PGR; IGF1R |
hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 1.207E-03 | 2.544E-03 | GSK3B; AKT1; MAPK1; PIK3R1; PIK3CG; IGF1R |
hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 5.950E-04 | 1.327E-03 | INSR; AKT1; PPARG; PIK3R1; PIK3CG; IGF1R |
hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 8.594E-04 | 1.853E-03 | INSR; AKT1; MAPK1; PIK3R1; PIK3CG; IGF1R |
hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 2.077E-03 | 4.181E-03 | CAMK2B; SRC; MAPK1; PIK3R1; PIK3CG; MYLK |
hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 9.022E-03 | 1.591E-02 | SRC; MAPK1; PIK3R1; PTK2; PIK3CG; MYLK |
hsa05164 | Influenza A_Homo sapiens_hsa05164 | 3.452E-03 | 6.565E-03 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1; PIK3CG |
hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 2.822E-03 | 5.475E-03 | BACE1; APP; GSK3B; MAPK1; MAPT; HSD17B10 |
hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 1.923E-02 | 3.215E-02 | CSNK2A1; CDK1; TP53; NFKB1; TLR2 |
hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 6.675E-03 | 1.233E-02 | CAMK2B; GSK3B; CSNK2A1; TP53; PPARD |
hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 1.986E-02 | 3.246E-02 | AKT1; MAPK1; MAPT; TP53; NFKB1; CDC25B |
hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 7.915E-03 | 1.409E-02 | CAMK2B; AKT1; MAPK1; PIK3R1; PIK3CG |
hsa04142 | Lysosome_Homo sapiens_hsa04142 | 1.939E-02 | 3.215E-02 | NPC1; GAA; GLA; CTSD |
hsa04650 | Natural killer cell mediated cytotoxicity_Homo sapiens_hsa04650 | 2.620E-02 | 4.100E-02 | SYK; MAPK1; PIK3R1; PIK3CG |
hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 1.070E-03 | 2.281E-03 | SYK; AKT1; MAPK1; PIK3R1; PIK3CG |
hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 1.480E-03 | 3.054E-03 | PIK3R1; NFKB1; PTK2; PIK3CG; TLR2 |
hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 3.053E-03 | 5.864E-03 | MMP2; PIK3R1; MMP9; PTK2; PIK3CG |
hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 1.991E-02 | 3.246E-02 | GSK3B; CDK1; TP53; CDC25B |
hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 2.152E-02 | 3.450E-02 | GSK3B; MAPK1; MET; PTK2 |
hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 9.685E-03 | 1.693E-02 | CAMK2B; GSK3B; MAPK1; TYR |
hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 1.002E-02 | 1.736E-02 | CAMK2B; AKT1; PYGL; PPARA |
hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 6.990E-03 | 1.279E-02 | CAMK2B; SRC; MMP2; MAPK1 |
hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 2.535E-04 | 6.225E-04 | SYK; AKT1; MAPK1; PIK3R1; PIK3CG |
hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 7.539E-03 | 1.367E-02 | SYK; CSNK2A1; PARP1; NFKB1 |
hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 4.803E-04 | 1.096E-03 | SRC; PIK3R1; MET; PTK2; PIK3CG |
hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 1.904E-04 | 4.925E-04 | INSR; AKT1; PIK3R1; PIK3CG; IGF1R |
hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.401E-04 | 3.672E-04 | AKT1; MAPK1; PIK3R1; HIF1A; PIK3CG |
hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 2.287E-02 | 3.636E-02 | MAPK1; NFKB1; TLR2 |
hsa04971 | Gastric acid secretion_Homo sapiens_hsa04971 | 2.369E-02 | 3.737E-02 | CAMK2B; CA2; MYLK |
hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 2.049E-02 | 3.313E-02 | AKT1; PPARA; NFKB1 |
hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 1.685E-02 | 2.842E-02 | SRC; MAPK1; NFKB1 |
hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 2.467E-03 | 4.883E-03 | CXCR1; SRC; MET; NFKB1 |
hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 1.699E-05 | 6.105E-05 | INSR; MAPK1; PIK3R1; PIK3CG; NR3C2 |
hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 2.090E-03 | 4.181E-03 | RORC; STAT6; NFKB1; TLR2 |
hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 1.300E-02 | 2.231E-02 | AKR1B10; AKR1B1; GLA |
hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 7.822E-03 | 1.405E-02 | MAOA; DRD2; NFKB1 |
hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 6.172E-03 | 1.151E-02 | AKT1; PIK3R1; PIK3CG |
hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 6.701E-04 | 1.468E-03 | INSR; MAPK1; PIK3R1; PIK3CG |
hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 5.795E-03 | 1.092E-02 | ABCC1; ABCB1; ABCG2 |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 3.314E-04 | 7.745E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 2.886E-02 | 4.479E-02 | AKR1B10; AKR1B1 |
hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.060E-04 | 2.896E-04 | AKR1B10; GAA; AKR1B1; GLA |
hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 1.751E-03 | 3.576E-03 | MAPK1; PPARG; TP53 |
hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 2.552E-03 | 5.000E-03 | POLB; PARP1; APEX1 |
hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 1.545E-02 | 2.630E-02 | CA2; CA4 |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 6.736E-04 | 1.468E-03 | CYP1A2; XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | HTR1A |
C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | HTR1A |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR2C; HTR1A; HTR1A |
K00-K95: Diseases of the digestive system | Gastroesophageal reflux disease | K21 | HTR3A |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
K00-K95: Diseases of the digestive system | Gastrointestinal problems | K30-K31, Q40-Q41 | DRD2 |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; ADORA3; KDR |
NA: NA | Itching | NA | DRD2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; CA2; DRD2 |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TERT; TP53; KDR; KDR |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TERT; FLT3; FLT3; AURKB; TP53; TP53 |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; FAAH |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
Z00-Z99: Factors influencing health status and contact with health services | Hormonal contraceptives | Z30 | PGR |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
NA: NA | HIV infections | NA | AHR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; IGF1R |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
O00-O9A: Pregnancy, childbirth and the puerperium | Postpartum haemorrhage | O72 | DRD2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
Z00-Z99: Factors influencing health status and contact with health services | Female contraception | Z30 | PGR |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
NA: NA | False perceptions | NA | DRD2 |
NA: NA | Dyslipidemia | NA | PPARD |
C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
NA: NA | Hepatitis C virus infection | NA | ADORA3 |
I00-I99: Diseases of the circulatory system | Hemorrhoids | I84 | HTR2A |
C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1; PIK3CG |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; ADRA2C |
G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
NA: NA | Peripheral vasoconstriction | NA | DRD2 |
NA: NA | Peripheral sensory neuropathies | NA | HTR1A |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; DRD2 |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C; HTR2A; HTR3A |
E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA; HTR2C; HTR1B; HTR1D; HTR2A; HTR1A |
NA: NA | Miosis during ocular surgery | NA | PTGS1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR; PPARD |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperprolactinemia | E22.1 | DRD2 |
I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | CTSD; ADRA2C; DRD2; DRD2; HTR1A |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD2 |
C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2; KDR |
L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
NA: NA | Episode | NA | HTR1A |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA; HTR1D |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
NA: NA | Enthesopathy | NA | PIK3CG |
NA: NA | Corneal vascularity | NA | DRD2 |
I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | HTR1A |
I00-I99: Diseases of the circulatory system | Coronary heart disease | I25.1 | HTR2B |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; SRC; AURKB; TP53 |
K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR |
NA: NA | Anxiety disorders | NA | HTR1A |
I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | DRD2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CAMK2B; MAOA; HTR2C; ACHE; HTR1B; NR3C1; FAAH; HTR2A; HTR6; HTR6; CYP3A4; DRD2; HTR1A |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO; CTSD; NR3C1 |
C00-D49: Neoplasms | Multiple myeloma | C90 | AHR; TERT; SRC; IGF1R |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | DRD2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | NR3C2; FLT3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1; INSR |
NA: NA | Hyperaemia | NA | DRD2 |
C00-D49: Neoplasms | Liver cancer | C22 | TERT; IGF1R; KDR |
G00-G99: Diseases of the nervous system G00-G99 | Lateral sclerosis | G12.2 | HTR1A |
E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | PGR |
NA: NA | Colour dead tissues | NA | PTPN1 |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; PTGS1; IGF1R; MMP9; TP53; KDR |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
NA: NA | Schizoaffective disorder | NA | HTR1A |
NA: NA | Rheumatold arthritis | NA | PTGS1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; ESRRA; HSD11B1; INSR |
C00-D49: Neoplasms | Aggressive non-hodgkin's lymphoma | C81, C81-C86, C82-C85, C91-C95 | HTR2C |
H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; PIK3CG; PIK3CG |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Advanced stage Parkinson's disease | F02.3, G20 | DRD2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; HTR2C; ADRA2C; ADRA2B; HTR2A; DRD2 |
A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Idiopathic thrombocytopenic purpura | D69.3 | DRD2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | DRD3; HTR1A |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; RAB9A |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
E00-E89: Endocrine, nutritional and metabolic diseases | Eating disorder | E66, F50, I10-I16, I50 | HTR1A |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1 |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | MYLK; CA2; CA1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
K00-K95: Diseases of the digestive system | Gastric motility disorder | K22.4 | DRD3 |
L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; GSK3B; MAPT; ACHE; ACHE; ACHE; INSR; ADRA2C; HTR6; HTR6; HTR6; PPARG; PPARG; DRD2; HTR1A; HTR1A; APP |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5; SYK; DRD2 |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B; ESRRA; NR3C1; ADRA2C |
C00-D49: Neoplasms | AML | NA | FLT3; KDR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Hypoactive sexual desire disorder | F52.0 | HTR1A |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR |
I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C; DRD2 |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PGR; CYP19A1; PPARG |
C00-D49: Neoplasms | Endometrial cancer | C54.1 | PGR; PIK3CG; PIK3CG |
E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | HTR6; HTR3A; DRD3; DRD2 |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
NA: NA | Edema | NA | CA2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Eczema | L20-L30 | NR3C1 |
G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | NR3C1; PARP1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1 |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
C00-D49: Neoplasms | Breast cancer | C50 | AR; CA9; TERT; PIK3CG; FLT3; FLT3; IGF1R; INSR; CYP19A1; CDK1; DRD2; KDR; KDR; KDR |
NA: NA | Addiction | NA | HTR2A |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ABCB1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Addison's disease | E27.1-E27.2 | NR3C2 |
C00-D49: Neoplasms | Advanced breast carcinoma | NA | PGR |
C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; CYP19A1 |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; ABCB1; AXL; IGF1R; IGF1R; DRD2; KDR |
NA: NA | Non-infectious rhinitis | NA | NR3C1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; HTR2C; HTR2C; HSD11B1; ADRA2C; HTR6; PPARG; PPARD; PPARD |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; NR3C2; XDH; ADRA2C |
G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; PTGS1 |
H00-H59: Diseases of the eye and adnexa | Diabetic retinopathy | H36, E10.3, E11.3, E13.3 | SERPINA6 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic macular edema | E08-E13, E08.3, E09.3, E10.3, E11.3, E13.3, H35.8, R60.9 | SERPINA6 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | NR3C2; ADRA2C; MMP1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; CA1 |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR |
C00-D49: Neoplasms | Advanced endometrium carcinoma | NA | PGR |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE; HTR6 |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; PTGS1; ADRA2B |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | HTR2C; ADRA2C; NPSR1; HTR6; APP |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
C00-D49: Neoplasms | Diffuse large B-cell lymphoma | C83.3 | PIK3CG |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | HTR2C; PPARG; DRD3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
G00-G99: Diseases of the nervous system G00-G99 | Duchenne muscular dystrophy | G71.0 | NR3C1 |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
J00-J99: Diseases of the respiratory system | Nasal congestion | J34.89 | DRD2 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | HTR3A; HTR3A; DRD2 |
I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | PIK3CG; MMP3; PARP1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Cushing's disease | E24.0 | NR3C1 |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA; NR3C1 |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | HTR1D |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; AKT1; PIK3CG; PIK3CG; INSR; HIF1A |
A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; HTR2C; NR3C1; ADRA2C; HTR2B; HTR2A; HTR1A |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | HTR6 |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; ALOX5; PTGS1; NR3C1 |
K00-K95: Diseases of the digestive system | Dermal necrosis | K05 | DRD2 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Depressive fatigue | R53.82 | DRD2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; AKR1B1; GSK3B; PTPN1; HTR2C; HSD11B1; HSD11B1; INSR; HTR2A; PPARG |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESRRA; MMP2; PTGS1 |
C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
I00-I99: Diseases of the circulatory system | Pulmonary hypertension | I27.0, I27.2 | DRD2 |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1; MMP9 |
NA: NA | Upper abdominal bloating | NA | ACHE |
C00-D49: Neoplasms | Uterine fibroids | D25 | PGR |
NA: NA | Inflammatory diseases | NA | DRD2 |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; SERPINA6; PLA2G1B; ALOX5; MMP13; SYK; PIK3CG; PTGS1; NR3C1; FAAH; DRD2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PPARG; DRD2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; ADORA3; NR3C1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; ACHE; HTR6; HTR1A |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD3 |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Chronic schizophrenics | F20 | HTR1B |
E00-E89: Endocrine, nutritional and metabolic diseases | Erythropoietic porphyria | E80.0 | HTR2A |
K00-K95: Diseases of the digestive system | Pancreatitis | K85, K86.0K86.1 | HTR2A |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOA; ACHE; DRD2; HTR1A |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; MMP13; HTR2C; ACHE; PTGS1; IGF1R; INSR; CDK1; ADRA2C; ADRA2A; FAAH; DRD2; HTR1A |
C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; TLR2; TERT; FLT3; MMP2; KDR |
NA: NA | Obstructive airway diseases | NA | SERPINA6 |
NA: NA | Benign prostatic hypertrophy | NA | DRD2 |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR; PPARG; PPARD |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | HTR2B; HTR3A |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC; ADORA3 |
I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
N00-N99: Diseases of the genitourinary system | Chronic kidney disease | N18 | NR3C2 |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ALOX5; NR3C1; NR3C1; NR3C1; DRD2 |
H60-H95: Diseases of the ear and mastoid process | Otitis externa | H60 | NR3C1 |
C00-D49: Neoplasms | Ovarian cancer | C56 | TERT; ABCB1; MMP2; PARP1; KDR; KDR; KDR; KDR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; PGR; SRC |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B; SRC |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; KDR |
K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARG; PPARD |
C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK; PIK3CG; PIK3CG |
C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; TLR2; TERT; PIK3CG; FLT3 |
N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
O00-O9A: Pregnancy, childbirth and the puerperium | Premature labour | O60.1, P07.3 | PGR |
NA: NA | Primary insomnia | NA | HTR2C |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA; TYR |
NA: NA | Vomiting | NA | HTR3A; DRD2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | DRD2; DRD2; DRD2; DRD2 |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PTK2; TP53 |
A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3 |
C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; KDR |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5; SYK |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | NR3C2 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP13; MMP3; MMP2; PTGS1 |
N00-N99: Diseases of the genitourinary system | Gynecological disorder | N70-N98 | PGR |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | HTR2C; HTR1B; DRD3; DRD4; DRD2; HTR1A |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychoses | F20-F29 | HTR2B |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | HTR2A; HTR1A |
K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; HTR2B |
C00-D49: Neoplasms | Uterine leiomyoma | D25 | PGR |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1 |
H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Local anaesthetic | R20.0 | HTR3A |
E00-E89: Endocrine, nutritional and metabolic diseases | Cerebral salt-wasting syndrome | E87.1 | NR3C2 |
I00-I99: Diseases of the circulatory system | Cerebral infarction | I63 | HTR2B |
I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; HTR2A; PPARD |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; PARP1; DRD2 |
C00-D49: Neoplasms | CLL | NA | FLT3 |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1; ADRA2C; CA4; CA4 |
H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | NR3C1; ADRA2C |
H00-H59: Diseases of the eye and adnexa | Ophthalmic disease | H00-H59 | DRD2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep maintenance insomnia | F51.0, G47.0 | HTR2A |
E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A; DRD2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | NR3C1; HTR1D; HTR1A; HTR1A |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HTR7; HTR2A |
NA: NA | Sleep initiation and maintenance disorders | NA | HTR2C |
S00-T88: Injury, poisoning and certain other consequences of external causes | Skin allergies | T78.4 | NR3C1 |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; PGR |
H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
NA: NA | Angioedema | NA | PIK3CG |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA; HTR2C; HTR2C; HTR1B; HTR7; HTR1D; FAAH; DRD2; HTR1A; HTR1A |
I00-I99: Diseases of the circulatory system | Maintain blood pressure in hypotensive states | I10 | DRD2 |
NA: NA | Male hypogonadism | NA | AR |
A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; CYP2D6 |
I00-I99: Diseases of the circulatory system | Cardiac failure | I50 | DRD2 |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; NR3C2; PIK3CG; HTR2A; KDR |
I00-I99: Diseases of the circulatory system | Cardiotonic | I50 | DRD2 |
J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5; NR3C1 |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Spasm | R25.2 | HTR1A |
C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9; AKT1; MET; TLR2; ABCB1; SYK; PIK3CG; FLT3; MMP2; SRC; IGF1R; PTK2; AURKB; HIF1A; MAPK1; MMP9; TP53; KDR; KDR; KDR; TOP2A |
S00-T88: Injury, poisoning and certain other consequences of external causes | Spinal cord injury | S14, S24, S34 | NR3C1 |
NA: NA | Social phobia | NA | HTR1A |
I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
NA: NA | Cervical dystonia | NA | HTR1A |
C00-D49: Neoplasms | Melanoma | C43 | TLR2; TERT; PARP1; TYR; KDR; KDR |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
NA: NA | Malignant phaeochromocytoma | NA | DRD2 |
NA: NA | Malignant essential hypertension | NA | DRD2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Carcinoid syndrome | E34.0 | DRD2 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
C00-D49: Neoplasms | Cancer | C00-C96 | AR; CA9; AKT1; MET; PGR; TLR2; NR3C2; GSK3B; CSNK2A1; ABCB1; CDC25B; SYK; PIK3CG; FLT3; FLT3; MMP2; ACHE; SRC; IGF1R; PTK2; ADORA3; HIF1A; CDK1; MAPK1; MMP9; NFKB1; NR3C1; PIM1; PARP1; TP53; CA1; KDR; APP |
J00-J99: Diseases of the respiratory system | Bronchitis | J20-J21, J42 | DRD2 |
NA: NA | Bulimia nervosa | NA | HTR1A |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C; DRD3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Xerophthalmia | E50.6-E50.7 | NR3C1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Acromegaly | E22.0 | DRD2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychosis | F20-F29 | DRD2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Fabry's disease | E75.2 | GLA |
NA: NA | Schizoaffective disorders | NA | DRD2 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CAMK2B; AKR1B1; PLA2G1B; ESRRA; ALOX5; SYK; MMP3; NR3C1; TYR; MMP1 |
NA: NA | Corticosteroid-responsive inflammation | NA | NR3C1 |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC |
I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
J00-J99: Diseases of the respiratory system | Asthma | J45 | SERPINA6; PLA2G1B; ESRRA; ALOX5; ALOX5; SYK; SYK; NR3C1; NR3C1; NR3C1; NR3C1; ADRA2C; DRD2 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ESRRA; ALOX5; PIK3CG; MMP1 |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | NR1I2; ALOX5; HSD11B1; PPARD |
N00-N99: Diseases of the genitourinary system | Menstrual disorders | N91-N95 | PGR |
C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HTR2C; HSD11B1; GPBAR1 |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | PIK3CG; KDR |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR; KDR |
C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT; SRC |
S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA; HTR2C; HTR7; HTR2A; HTR2A; HTR6; DRD3; DRD4; DRD2; DRD2; DRD2; DRD2; HTR1A; HTR1A |
I00-I99: Diseases of the circulatory system | Congestive heart failure | I50 | NR3C2; HTR2B |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5; NR3C1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2; SYK; INSR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | ABCB1; PIK3CG; CYP2C9; DRD2 |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP |
G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | HTR2C; HTR1B; HTR1D; DRD2 |
G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | HTR1F; HTR1D; HTR2B; HTR2A; CYP2D6; HTR1A |
C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; XDH; PPARG |
C00-D49: Neoplasms | Glioma | C71 | PIK3CG; KDR; APP |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
NA: NA | GIST | NA | FLT3 |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; ACHE; ADORA3; ADRA2C; HTR2A; CA1; CA1; DRD2 |
NA: NA | Geographic retinal atrophy | NA | APP |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; NR3C2; PTPN1; PTPN1; PIK3CG; PIK3CG; HSD11B1; INSR; NFKB1; NR3C1; PPARG; PPARG; GPBAR1; PPARD |
C00-D49: Neoplasms | Tumors | C00-D48 | TERT |